RecombiMAb anti-mouse CD71 (TfR1)

Catalog #CP055
Clone:
8D3-CP055

$541.00 - $7,325.00

$541.00 - $7.00

Choose an Option...
  • 25 mg - $7,325.00
  • 5 mg - $2,097.00
  • 1 mg - $541.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left
Isotype:
Mouse IgG2a, kappa
(switched from rat IgG2a, kappa)

Product Details

The CP055 monoclonal antibody is a recombinant, chimeric version of the original 8D3 antibody. The variable domain sequences are identical to the original 8D3 but the constant region sequences have been switched from rat IgG2a to mouse IgG2a, kappa for use in murine models. Species-matched chimeric antibodies exhibit regulated effector functions—including Fc receptor binding and complement activation—and result in less immunogenicity and formation of anti-drug antibodies (ADAs) than xenogenic antibodies in animal models. The anti-tumor and cytotoxic activities of anti-TfR1 antibodies have been demonstrated to require Fc effector function to elicit antibody-dependent cell-mediated cytotoxicity and antibody-dependent cell-mediated phagocytosis. The 8D3 monoclonal antibody reacts with native, soluble and denatured forms of murine CD71, also known as transferrin receptor protein 1 (TfR1). CD71 is a type II homodimeric transmembrane glycoprotein expressed on the surface of proliferating cells, reticulocytes, and erythroid precursors. CD71 plays a role in the control of cellular proliferation and is required for iron import from transferrin into cells by endocytosis. CD71 is overexpressed on many different types of cancer cells and expression level correlates with advanced stage and/or poorer prognosis in several cancers, including solid cancers. Elevated levels of CD71 expression on malignant cells, together with its extracellular accessibility, ability to internalize, and central role in cancer cell pathology make this receptor an attractive target for antibody-mediated therapy. In addition, cells of the vascular endothelium of brain capillaries that compose the blood-brain barrier (BBB) also express high levels of CD71 allowing for receptor-mediated transcytosis of large biomolecules into the brain. Chimeric anti-CD71 clone 8D3 has been used as a BBB transporter in mice and is suitable for studying CD71 expression and iron uptake into different tissues.

Specifications

Isotype Mouse IgG2a, Īŗ
Recommended Isotype Control(s) RecombiMAb mouse IgG2a isotype control, unknown specificity
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Conjugation This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
Immunogen Mouse transformed endothelioma cell line t.end1
Reported Applications Targeted drug delivery to the brain
Immunohistochemistry
Flow Cytometry
Western Blot
In vivo depletion of CD71+ cells
In vivo anti-tumor activity
*Reported for the original 8D3 antibody. For information on in vivo applications, please contact technicalservice@bioxcell.com
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin <1EU/mg (<0.001EU/μg)
Determined by LAL gel clotting assay
Aggregation <5%
Determined by SEC
Purity >95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from HEK293 cell supernatant in an animal-free facility
Purification Protein G
Molecular Weight 150 kDa
Murine Pathogen Tests Ectromelia/Mousepox Virus: Negative
Hantavirus: Negative
K Virus: Negative
Lactate Dehydrogenase-Elevating Virus: Negative
Lymphocytic Choriomeningitis virus: Negative
Mouse Adenovirus: Negative
Mouse Cytomegalovirus: Negative
Mouse Hepatitis Virus: Negative
Mouse Minute Virus: Negative
Mouse Norovirus: Negative
Mouse Parvovirus: Negative
Mouse Rotavirus: Negative
Mycoplasma Pulmonis: Negative
Pneumonia Virus of Mice: Negative
Polyoma Virus: Negative
Reovirus Screen: Negative
Sendai Virus: Negative
Theiler’s Murine Encephalomyelitis: Negative
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
in vivo anti-tumor activity
Candelaria PV, Leoh LS, Penichet ML, Daniels-Wells TR. (2021). "Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents" Front Immunol . PubMed

The transferrin receptor 1 (TfR1), also known as cluster of differentiation 71 (CD71), is a type II transmembrane glycoprotein that binds transferrin (Tf) and performs a critical role in cellular iron uptake through the interaction with iron-bound Tf. Iron is required for multiple cellular processes and is essential for DNA synthesis and, thus, cellular proliferation. Due to its central role in cancer cell pathology, malignant cells often overexpress TfR1 and this increased expression can be associated with poor prognosis in different types of cancer. The elevated levels of TfR1 expression on malignant cells, together with its extracellular accessibility, ability to internalize, and central role in cancer cell pathology make this receptor an attractive target for antibody-mediated therapy. The TfR1 can be targeted by antibodies for cancer therapy in two distinct ways: (1) indirectly through the use of antibodies conjugated to anti-cancer agents that are internalized by receptor-mediated endocytosis or (2) directly through the use of antibodies that disrupt the function of the receptor and/or induce Fc effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), or complement-dependent cytotoxicity (CDC). Although TfR1 has been used extensively as a target for antibody-mediated cancer therapy over the years, interest continues to increase for both targeting the receptor for delivery purposes and for its use as direct anti-cancer agents. This review focuses on the developments in the use of antibodies targeting TfR1 as direct anti-tumor agents.

transport across the BBB
Boado RJ, Zhang Y, Wang Y, Pardridge WM. (2009). "Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse" Biotechnol Bioeng 102(4):1251-8. PubMed

Protein therapeutics may be delivered across the blood-brain barrier (BBB) by genetic fusion to a BBB molecular Trojan horse. The latter is an endogenous peptide or a peptidomimetic monoclonal antibody (MAb) against a BBB receptor, such as the insulin receptor or the transferrin receptor (TfR). Fusion proteins have been engineered with the MAb against the human insulin receptor (HIR). However, the HIRMAb is not active against the rodent insulin receptor, and cannot be used for drug delivery across the mouse BBB. The rat 8D3 MAb against the mouse TfR is active as a drug delivery system in the mouse, and the present studies describe the cloning and sequencing of the variable region of the heavy chain (VH) and light chain (VL) of the rat 8D3 TfRMAb. The VH and VL were fused to the constant region of mouse IgG1 heavy chain and mouse kappa light chain, respectively, to produce a new chimeric TfRMAb. The chimeric TfRMAb was expressed in COS cells following dual transfection with the heavy and light chain expression plasmids, and was purified by protein G affinity chromatography. The affinity of the chimeric TfRMAb for the murine TfR was equal to the 8D3 MAb using a radio-receptor assay and mouse fibroblasts. The chimeric TfRMAb was radio-labeled and injected into mice for a pharmacokinetics study of the clearance of the chimeric TfRMAb. The chimeric TfRMAb was rapidly taken up by mouse brain in vivo at a level comparable to the rat 8D3 MAb. In summary, these studies describe the genetic engineering, expression, and validation of a chimeric TfRMAb with high activity for the mouse TfR, which can be used in future engineering of therapeutic fusion proteins for BBB drug delivery in the mouse.